A risk benefit assessment of methotrexate in corticosteroid dependent asthma

Drug Safety

Volumn 15, Issue 4, 1996, Pages 283-290

  Shulimzon, Tiberiu R ^b   Shiner, Robert J ^a  

^a SHEBA MEDICAL CENTER   (Israel)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; FOLIC ACID ANTAGONIST; METHOTREXATE;

ANTIINFLAMMATORY ACTIVITY; ASTHMA; DRUG EFFICACY; HUMAN; LIVER TOXICITY; LUNG TOXICITY; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS;

EID: 0029958272     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-199615040-00006     Document Type: Review

References (51)

1. Weinblatt ME, Coblyn JS, Fox DA, et al. Efficacy of low dose methotrexate in rheumatoid arthritis. N Engl J Med 1985; 312: 818-22
2. Giannini EH, Brewer EJ, Kuzmina N, et al. Methotrexate in resistant juvenile rheumatoid arthritis: results of the USA/USSR double blind placebo controlled trial. N Engl J Med 1990; 326: 1043-9
3. Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn's disease. N Engl J Med 1995; 332: 292-7
4. Gubner R, August S, Ginsberg V, et al. Therapeutic suppression of tissue reactivity I: effect of aminopterin in rheumatoid arthritis and psoriasis. Am J Med Sci 1951; 221: 176-82
5. Kaplan RL, Waite DH. Progressive interstitial lung disease from prolonged methotrexate therapy. Arch Dermatol 1978; 114: 1800-2
6. Kremer JM. The mechanism of action of methotrexate in rheumatoid arthritis, the search continues. J Rheumatol 1994; 21: 1-5
7. Cronstein BN, Naime D, Ostad E. The antiinflammatory mechanism of methotrexate: increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J Clin Invest 1993; 92: 2675-82
8. Reid DJ, Segars LW. Methotrexate for the therapy of chronic steroid dependent asthma. Clin Pharm 1993; 12: 762-7
9. Glynn-Barnhart ASC, Erzurum SC, Leff JA, et al. Effect of low dose methotrexate on the disposition of glucocorticosteroids and theophylline. J Allergy Clin Immunol 1991; 88/2: 180-6
10. Mullarkey MF, Blumenstein BA, Andrade WP, et al. Methotrexate in the treatment of corticosteroid dependent asthma. N Engl J Med 1988; 318: 603-7
11. Shiner RJ, Nunn AJ, Chung KF, et al. Randomised, double blind, placebo controlled trial of methotrexate in steroid dependent asthma. Lancet 1990; 336: 137-40
12. Dyer PD, Vaughan TR, Weber RW. Methotrexate in the treatment of steroid-dependent asthma. J Allergy Clin Immunol 1991; 88: 208-12
13. Stewart II GE, Diaz JD, Lockey RF, et al. Comparison of oral pulse methotrexate with placebo in the treatment of severe glucocorticosteroid dependent asthma. J Allergy Clin Immunol 1994; 94: 482-9
14. Trigg CJ, Davies RJ. Comparison of methotrexate 30 mg/week with placebo in chronic steroid dependent asthma: a 12 week double blind crossover study. Respir Med 1993; 87: 211-6
15. Coffey MJ, Sanders G, Eschenbacher WL. The role of methotrexate in the management of steroid dependent asthma. Chest 1994; 105: 117-21
16. Erzurum S, Leff JA, Evans Cochran J. Lack of benefit of methotrexate in severe steroid dependent asthma. Ann Int Med 1991; 114: 353-60
17. NIH International Consensus Report on diagnosis and therapy of asthma. Washington, DC: US Government Printing Office, 1991; 92: 3091
18. Shiner RJ, Geddes DM. Corticosteroids in asthma. Chest 1990; 97: 1021
19. Mullarkey MF, Webb DR, Pardee NE. Methotrexate in the treatment of steroid dependent asthma. Ann Allergy 1986; 56: 347-50
20. Mullarkey MF, Lammert JK, Blumenstein BA. Long term methotrexate therapy in corticosteroid dependent asthma. Ann Intern Med 1990; 112: 577-81
21. Shiner RJ, Katz I, Shulimzon T, et al. Methotrexate in steroid dependent asthma: long term results. Allergy 1994; 49: 565-8
22. Domingo CH, Ferrer A, Torremorell MD, et al. Methotrexate as a steroid sparing agent in bronchial asthma: preliminary results [abstract]. Chest 1994; 106 Suppl.: 108
23. Felleti R, Cerri E, Mangano A, et al. Follow up in a larger group of patients: methotrexate treatment in corticosteroid dependent asthma patients [abstract]. Eur Respir J 1992; 5: Suppl. 15: 13
24. Kimura I, Tada S. Methotrexate in the treatment of bronchial asthma. Kokyu To Junkan 1991; 10: 566-70
25. Bardin PG, Johnston SL, Holgate ST. Antiinflammatory strategies for the treatment of asthma. S Afr Med J 1992; 81: 303-9
26. Edward N, Squire JR, Lombardo FA. If methotrexate fails to control asthma other regimens do too. J Allergy Clin Immunol 1993; 91: 168
27. Edward N, Squire JR, Lombardo FA. Methotrexate may successfully control severe asthma when hydroxychloroquine and/or troleandomycin fail but not vice versa. J Allergy Clin Immunol 1992; 89: 286
28. Moss RB. Alternative pharmacotherapies for steroid dependent asthma. Chest 1995; 107: 817-25
29. Hill JM, Tattersfield AE. Corticosteroid sparing agents in asthma. Thorax 1995; 50: 577-82
30. Stempel DA, Lammert J, Mullarkey MF. Use of methotrexate in the treatment of steroid dependent adolescent asthmatics. Ann Allergy 1991; 67: 346-8
31. Guss S, Portnoy J. Methotrexate treatment of severe asthma in children. Pediatrics 1992; 89: 635-9
32. Fertel D, Wanner A. Methotrexate: does it treat or induce asthma? Am Rev Respir Dis 1991; 143: 1-2
33. Jones G, Mierins E, Karsh J. Methotrexate induced asthma. Am Rev Respir Dis 1991; 143: 179-81
34. Chung KF, Geddes DM, Shiner RJ. Methotrexate: does it treat or induce asthma [letter]. Am Rev Respir Dis 1992; 733
35. Taylor DR, Flannery EM, Herbison JP. Methotrexate in the management of severe steroid dependent asthma. NZ Med J 1993; 106: 409-11
36. Lock SH, Kay AB, Barnes NC. Double blind, placebo controlled study of cyclosporin A as a corticosteroid-sparing agent in cortico steroid dependent asthma. Am J Respir Crit Care Med 1996; 153: 509-14
37. Vallerand H, Cossart C, Milosevic D, et al. Fatal Pn. carini pneumonia in asthmatic patient treated with methotrexate [letter]. Lancet 1992; 339: 1551
38. Shulimzon T, Weiss P, Shiner RJ, et al. Long term methotrexate treatment (up to six years) in steroid dependent asthma [abstract]. European Respiratory Society Annual Congress: 1996 Sep 7-11; Stockholm
39. Alarcon GS, Tracy IC, Blackburn WD. Methotrexate in rheumatoid arthritis: toxic effects as the major factor in limiting long term treatment. Arthritis Rheum 1989; 32: 671-6
40. Tishler M, Caspi D, Rosenbach TO. Methotrexate in rheumatoid arthritis. Ann Rheum Dis 1988; 47: 654-9
41. Kremer JM, Lee J K. The safety and efficacy of the use of methotrexate in long term therapy of rheumatoid arthritis. Arthritis Rheum 1986; 29: 822-31
42. Tugwell P, Bennett K, Gent M. Methotrexate in rheumatoid arthritis indications, contraindications, efficacy and safety. Ann Intern Med 1987; 107: 358-66
43. Jurgens H, Gobell U. Pharmacology, toxicology and drug interaction methotrexate. Rheumatology 1986; 9: 6-19
44. Health and Public Policy Committee, American College of Physicians. Methotrexate in rheumatoid arthritis. Ann Intern Med 1987; 107: 518-9
45. Geddes DM. Methotrexatt in asthma. Clin Exp Allergy 1991; 21: 541-3
46. Sostman HD, Matthay RA. Methotrexate induced pneumonia. Medicine 1976; 55: 371-88
47. Wollner A, Mohle-Boetani J, Lambert RE, et al. Pn. carinii and low dose methotrexate. Thorax 1991; 46: 205-7
48. Kuitert LM, Harrison AC. Pneumocystis carinii pneumonia as a complication of methotrexate therapy of asthma. Thorax 1991; 46: 936-7
49. Altz-Smith M, Kendall LG, Stamm AM. Cryptococcosis associated with low dose methotrexate for arthritis. Am J Med 1987; 83: 179-81
50. Keegan JM, Byrd JW. Nocardiosis associated with low dose methotrexate for rheumatoid arthritis [letter]. J Rheumatol 1988; 15: 1585-6
51. Nyfors A, Jensen H. Frequency of malginant neoplasms in 248 long term methotrexate treated psoratics. Dermatologica 1983; 167: 260-1